Sulzer Ltd is set to acquire Swiss-German drug delivery device manufacturer Haselmeier for EUR 100 million, enhancing its healthcare portfolio and leveraging advanced technology for growth in the rapidly evolving market.

Information on the Target

Sulzer Ltd has made a strategic move to acquire Haselmeier, a privately held Swiss-German company specializing in the development and manufacturing of drug delivery devices, for an enterprise value of EUR 100 million. Haselmeier is renowned for its proprietary drug delivery devices, which include subcutaneous self-injection pens that are tailor-made for various burgeoning medical indications such as reproductive health, growth disorders, osteoporosis, and diabetes.

The company employs approximately 230 professionals and reported sales of EUR 36 million in 2019. By integrating Haselmeier’s innovative solutions into its existing operations, Sulzer aims to enhance its healthcare portfolio and capitalize on growth opportunities within the rapidly evolving drug delivery devices market.

Industry Overview

The drug delivery device industry, particularly in Europe, is experiencing significant expansion driven by an aging population and an increasing prevalence of chronic illnesses. This sector is entering a phase marked by technological advancements, with c